Jeremy M Shefner1,2, Merit E Cudkowicz3, Orla Hardiman4, Bettina M Cockcroft5, Jacqueline H Lee5, Fady I Malik5, Lisa Meng5, Stacy A Rudnicki5, Andrew A Wolff5, Jinsy A Andrews6. 1. Barrow Neurological Institute, Phoenix, Arizona. 2. Department of Neurology, University of Arizona, Phoenix, AZ, USA. 3. Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA. 4. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland. 5. Cytokinetics, Inc., South San Francisco, California, USA. 6. The Neurological Institute, Columbia University, New York, NY, USA.
Abstract
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: −16.8, −11.9) in the placebo group and 13.4% (95% CI: −15.3, −11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898).
RCT Entities:
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: −16.8, −11.9) in the placebo group and 13.4% (95% CI: −15.3, −11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898).
Authors: Martijn van de Locht; Sandra Donkervoort; Josine M de Winter; Stefan Conijn; Leon Begthel; Benno Kusters; Payam Mohassel; Ying Hu; Livija Medne; Colin Quinn; Steven A Moore; A Reghan Foley; Gwimoon Seo; Darren T Hwee; Fady I Malik; Thomas Irving; Weikang Ma; Henk L Granzier; Erik-Jan Kamsteeg; Kalyan Immadisetty; Peter Kekenes-Huskey; José R Pinto; Nicol Voermans; Carsten G Bönnemann; Coen Ac Ottenheijm Journal: J Clin Invest Date: 2021-05-03 Impact factor: 14.808
Authors: Josine M de Winter; Charlotte Gineste; Elisa Minardi; Lorenza Brocca; Maira Rossi; Tamara Borsboom; Alan H Beggs; Monique Bernard; David Bendahan; Darren T Hwee; Fady I Malik; Maria Antonietta Pellegrino; Roberto Bottinelli; Julien Gondin; Coen A C Ottenheijm Journal: Hum Mol Genet Date: 2021-06-26 Impact factor: 6.150
Authors: Lisanne Roesthuis; Hans van der Hoeven; Christer Sinderby; Tim Frenzel; Coen Ottenheijm; Laurent Brochard; Jonne Doorduin; Leo Heunks Journal: Intensive Care Med Date: 2019-10-01 Impact factor: 17.440
Authors: Charis Wong; Maria Stavrou; Elizabeth Elliott; Jenna M Gregory; Nigel Leigh; Ashwin A Pinto; Timothy L Williams; Jeremy Chataway; Robert Swingler; Mahesh K B Parmar; Nigel Stallard; Christopher J Weir; Richard A Parker; Amina Chaouch; Hisham Hamdalla; John Ealing; George Gorrie; Ian Morrison; Callum Duncan; Peter Connelly; Francisco Javier Carod-Artal; Richard Davenport; Pablo Garcia Reitboeck; Aleksandar Radunovic; Venkataramanan Srinivasan; Jenny Preston; Arpan R Mehta; Danielle Leighton; Stella Glasmacher; Emily Beswick; Jill Williamson; Amy Stenson; Christine Weaver; Judith Newton; Dawn Lyle; Rachel Dakin; Malcolm Macleod; Suvankar Pal; Siddharthan Chandran Journal: Brain Commun Date: 2021-10-23